L-Citrulline increases nitric oxide and improves control in obese asthmatics.
Adult
Aged
Arginine
/ analogs & derivatives
Asthma
/ blood
Citrulline
/ administration & dosage
Dietary Supplements
Female
Forced Expiratory Volume
Humans
Male
Middle Aged
Nitric Oxide
/ blood
Nitric Oxide Synthase Type II
/ metabolism
Obesity
/ blood
Oxidative Stress
/ drug effects
Pilot Projects
Proof of Concept Study
Severity of Illness Index
Treatment Outcome
Young Adult
Asthma
Pulmonology
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
19 12 2019
19 12 2019
Historique:
received:
11
07
2019
accepted:
06
11
2019
pubmed:
13
11
2019
medline:
21
10
2020
entrez:
13
11
2019
Statut:
epublish
Résumé
BACKGROUNDThe airways of obese asthmatics have been shown to be NO deficient, and this contributes to airway dysfunction and reduced response to inhaled corticosteroids. In cultured airway epithelial cells, L-citrulline, a precursor of L-arginine recycling and NO formation, has been shown to prevent asymmetric dimethyl arginine-mediated (ADMA-mediated) NO synthase (NOS2) uncoupling, restoring NO and reducing oxidative stress.METHODSIn a proof-of-concept, open-label pilot study in which participants were analyzed before and after treatment, we hypothesized that 15 g/d L-citrulline for 2 weeks would (a) increase the fractional excretion of NO (FeNO), (b) improve asthma control, and (c) improve lung function. To this end, we recruited obese (BMI >30) asthmatics on controller therapy, with a baseline FeNO of ≤30 ppb from the University of Colorado Medical Center and Duke University Health System.RESULTSA total of 41 subjects with an average FeNO of 17 ppb (95% CI, 15-19) and poorly controlled asthma (average asthma control questionnaire [ACQ] 1.5 [95% CI, 1.2-1.8]) completed the study. Compared with baseline, L-citrulline increased whereas ADMA and arginase concentration did not (values represent the mean Δ and 95% CI): plasma L-citrulline (190 μM, 84-297), plasma L-arginine (67 μM, 38-95), and plasma L-arginine/ADMA (ratio 117, 67-167). FeNO increased by 4.2 ppb (1.7-6.7 ppb); ACQ decreased by -0.46 (-0.67 to 0.27 points); the forced vital capacity and forced exhalation volume in 1 second, respectively, changed by 86 ml (10-161 ml) and 52 ml (-11 to 132 ml). In a secondary analysis, the greatest FEV1 increments occurred in those subjects with late-onset asthma (>12 years) (63 ml [95% CI, 1-137]), in females (80 ml [95% CI, 5-154]), with a greater change seen in late-onset females (100 ml, [95% CI, 2-177]). The changes in lung function or asthma control were not significantly associated with the changes before and after treatment in L-arginine/ADMA or FeNO.CONCLUSIONShort-term L-citrulline treatment improved asthma control and FeNO levels in obese asthmatics with low or normal FeNO. Larger FEV1 increments were observed in those with late-onset asthma and in females.TRIAL REGISTRATIONClinicalTrials.gov NCT01715844.FUNDINGNIH NHLBI R01 HL146542-01.
Identifiants
pubmed: 31714895
pii: 131733
doi: 10.1172/jci.insight.131733
pmc: PMC6975256
doi:
pii:
Substances chimiques
Citrulline
29VT07BGDA
Nitric Oxide
31C4KY9ESH
N,N-dimethylarginine
63CV1GEK3Y
Arginine
94ZLA3W45F
NOS2 protein, human
EC 1.14.13.39
Nitric Oxide Synthase Type II
EC 1.14.13.39
Banques de données
ClinicalTrials.gov
['NCT01715844']
Types de publication
Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL146542
Pays : United States
Références
Eur Respir J. 2006 Mar;27(3):495-503
pubmed: 16507848
Clin Exp Allergy. 2007 Jul;37(7):1049-54
pubmed: 17581198
Am J Respir Crit Care Med. 2010 Feb 15;181(4):315-23
pubmed: 19892860
Am J Respir Crit Care Med. 2013 Jan 15;187(2):153-9
pubmed: 23204252
Pediatr Pulmonol. 2010 Mar;45(3):236-40
pubmed: 20131381
Br J Nutr. 2008 Apr;99(4):855-62
pubmed: 17953788
J Allergy Clin Immunol. 2004 Jan;113(1):101-8
pubmed: 14713914
Br J Clin Pharmacol. 2008 Jan;65(1):51-9
pubmed: 17662090
Am J Respir Cell Mol Biol. 2007 May;36(5):520-8
pubmed: 17158357
Am J Respir Cell Mol Biol. 2010 Jan;42(1):3-8
pubmed: 19648472
Nutr Diabetes. 2017 Feb 20;7(2):e244
pubmed: 28218737
Thorax. 1999 Nov;54(11):1033-5
pubmed: 10525564
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1358-1367
pubmed: 30682261
Ann Allergy Asthma Immunol. 2009 Aug;103(2):101-7
pubmed: 19739421
Clin Sci (Lond). 1995 Feb;88(2):135-9
pubmed: 7720336
J Asthma. 2006 Dec;43(10):731-4
pubmed: 17169823
Thorax. 2008 Jan;63(1):14-20
pubmed: 18156567
J Occup Med. 1988 Mar;30(3):272-3
pubmed: 3361365
Metabolism. 2004 Dec;53(12):1574-9
pubmed: 15562402
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30
pubmed: 15817806
Am J Respir Crit Care Med. 2011 Oct 1;184(7):779-85
pubmed: 21719758
J Nutr. 2007 Jun;137(6 Suppl 2):1693S-1701S
pubmed: 17513449
PLoS One. 2015 Jun 22;10(6):e0129850
pubmed: 26098111
Am J Respir Cell Mol Biol. 2009 Feb;40(2):179-88
pubmed: 18703795
Am J Respir Crit Care Med. 2008 Aug 1;178(3):218-224
pubmed: 18480428
J Appl Physiol (1985). 2010 Mar;108(3):754-9
pubmed: 19926826
J Breath Res. 2019 Mar 06;13(2):021002
pubmed: 30673653
Eur Respir J. 1999 Oct;14(4):902-7
pubmed: 10573240
Clin Exp Allergy. 2017 Feb;47(2):190-199
pubmed: 27562295
J Allergy Clin Immunol. 2010 Mar;125(3):626-35
pubmed: 20153031
Chest. 2013 Aug;144(2):405-410
pubmed: 23412513
Respir Res. 2007 Apr 16;8:32
pubmed: 17437645
Am J Respir Crit Care Med. 2004 Jul 15;170(2):148-53
pubmed: 15070820
J Physiol Biochem. 2018 Feb;74(1):9-16
pubmed: 29098611
Vasc Med. 2005 Jul;10 Suppl 1:S73-81
pubmed: 16444872
Curr Opin Pharmacol. 2018 Jun;40:126-133
pubmed: 29729549
Proc Am Thorac Soc. 2010 Sep;7(5):325-35
pubmed: 20844291
High Alt Med Biol. 2005 Winter;6(4):289-300
pubmed: 16351563
Allergy. 2006 Jan;61(1):79-84
pubmed: 16364160
J Asthma. 2010 Feb;47(1):76-82
pubmed: 20100025
J Pharmacol Exp Ther. 1994 Feb;268(2):978-84
pubmed: 7906736